Neurodegenerative Diseases: current treatment algorithm and potential investment opportunities covered in a lates research report

This report examines the entire neurodegenerative disease therapy area, with a particular focus on the three most prevalent neurodegenerative disorders: Alzheimer’s disease (AD), Parkinson’s disease (PD) and multiple sclerosis (MS).

Pune, India - March 14, 2018 /MarketersMedia/ —

AD and PD represent the most pressing challenges within the disease cluster, due to rapidly increasing prevalence driven by aging populations. Both AD and PD remain ineffectively treated despite substantial investment into R&D by pharmaceutical companies, due to high clinical trial failure rates. As a result there are no disease-modifying therapies for these two indications, with available treatments able to provide only marginal symptomatic relief. MS, the autoimmune disease of the CNS, contrasts with the rest of this cluster, as it affects a different population demographic, and has a lucrative pharmacological market following breakthrough success in the past decade.
Access Report Details at:
Reasons To Buy
• Appreciate the current clinical and commercial landscapes by considering disease symptoms, pathogenesis, etiology, co-morbidities and complications, epidemiology, diagnosis, prognosis and treatment options.
• Identify leading products and key unmet needs within the market.
• Recognize innovative pipeline trends by analyzing therapies by stage of development, molecule type and molecular target.
• Assess the therapeutic potential of first-in-class targets. Using proprietary matrix assessments, first-in-class targets in the pipeline have been assessed and ranked according to clinical potential. Individual matrix assessments are provided for targets categorized into four major classes: protein misfolding, neuromodulators, immunomodulators and neuroprotectants. The most promising first-in-class targets are reviewed in greater detail.
• Consider first-in-class pipeline products with no prior involvement in licensing and co-development deals, which may represent potential investment opportunities.
Get this report at:
• Unmet need is extremely high in AD and PD, with MS showing continued promise in the development of effective therapies
• What are the most important etiological risk factors and pathophysiological processes implicated in AD, PD and MS?
• What is the current treatment algorithm?
• How effective are current therapies for these indications, and how does this impact prognosis?
• The AD pipeline is large and contains a very high proportion of first-in-class product innovation.
• Which molecule types and molecular targets are most prominent across AD, PD and MS?
• What are the connections, in terms of first-in-class innovation, between AD, PD and MS?
• Which first-in-class targets are most promising?
Inquire for more details at:

Contact Info:
Name: Shirish Gupta
Organization: The Market Reports
Address: SF-29, Sacred World, Wanawadi
Phone: 16314071315

Source URL:

For more information, please visit

Source: MarketersMedia

Release ID: 314330

Latest News

China propaganda kicks into overdrive as 'helmsman' Xi re-anointed president

Mar 18, 2018

By Ben BlanchardBEIJING (Reuters) - With pictures of ecstatic citizens standing in applause, happily tearful legislators and even a social media game, China's propaganda drive has kicked into high gear following Xi Jinping's unanimous reappointment as president.Xi's face dominated the front pages of major Sunday newspapers, many carrying the same editorial from the ruling Communist Party's official People's Daily using language once more associated with Mao Zedong to say he was a "leader loved and respected by the people" and "helmsman of the country"."The voyage of a great country cannot do without a helmsman," the paper wrote.The military's official People's...

China plans tougher goals, beefed-up inspections in war on smog

Mar 18, 2018

BEIJING (Reuters) - China will set more stringent targets for improving the nation's air quality under a new three-year plan, as Beijing prepares to beef up a nationwide crackdown on polluters in its years-long campaign to clear its notoriously toxic skies.The new targets for concentrations of small, breathable particles known as PM2.5 will be lower than those in the country's current five-year plan that was due to end in 2020, environment minister Li Ganjie said at a briefing on the sidelines of the country's annual Parliament on Saturday.In January, the Ministry of Environmental Protection (MEP) said it was drawing up...'s finance unit aims to raise $1.9 billion, valuation set to double: sources

Mar 18, 2018

By Julie ZhuHONG KONG (Reuters) - Inc's finance arm is looking to raise about 12 billion yuan ($1.9 billion) in fresh equity that could see its value double from last year to more than $20 billion, three people with knowledge of the matter said.The unit of China's second-largest e-commerce firm is seeking to deepen its push into areas such as securities, banking and insurance - businesses that have seen the entry of several new technology-focused players.The move adds to a flurry of fundraising by Chinese tech firms keen to respond to burgeoning demand for digital services, especially in the...

Chamber of Commerce warns Trump against China tariffs

Mar 18, 2018

WASHINGTON (Reuters) - The head of the most influential U.S. business lobbying group warned the Trump administration that unilateral tariffs on Chinese goods could lead to a destructive trade war that will hurt American consumers and U.S. economic growth.U.S. Chamber of Commerce President Thomas Donohue said in a statement on Thursday that such tariffs, associated with a probe of China's intellectual property practices, would be "damaging taxes on American consumers."His comments came after White House trade adviser Peter Navarro said that Trump would in coming weeks get options to address China's "theft and forced transfer" of American intellectual property as...

Leshi shares plunge after 'white knight' chairman resigns

Mar 18, 2018

By Sijia JiangHONG KONG (Reuters) - Shares in Leshi Internet Information & Technology Corp Beijing slumped 10 percent on Friday after its chairman resigned, fanning fears he would no longer play a white knight role for the embattled firm.Sun Hongbin took on the job only eight months ago after a $2.2 billion investment by his property firm Sunac China Holdings, and had been seen as the main backer for the crumbling LeEco conglomerate, of which Leshi has been the main listed vehicle.But financial woes at LeEco, which once aspired to be both China's Netflix and Tesla, have only deepened with...

Sign up now!